Saturday, October 17, 2026 · Edition updated 6:00 AM ETSAT, OCT 17 · 6 AM ET editionNext edition in Next --:--:--

Noom study will track weight and health in two programs over two years

Opening soon · Noom Inc.

What this means

This study has not started recruiting people yet, so no results exist. It will compare several weight programs, including ones using GLP-1 medicines, over 24 months.

Plain-English summary written by an AI model from the registry listing.

Status
Opening soon
Who can join
Ages 18–64 · 2,310 participants planned, not yet enrolled
Where
1 site, including New Jersey

Contacts and how to join ↗

The science

Registered title
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
Phase
Not applicable
Study type
observational
Conditions
Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
What is tested
Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
Sponsor
Noom Inc.
Ages
18 Years to 64 Years
Dates
First posted May 15, 2026 · updated May 15, 2026

Registry summary

This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement.

FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).

THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control.

Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.

Sites (1)

  • Noom, Inc., Princeton, New Jersey, United States

Related treatments

GLP-1 drugs

More aging trials in these states

New Jersey

Report a problem